Navtemadlin (KRT-232) activity after failure of anti-PD-1/L1 therapy in patients (pts) with TP53WT Merkel cell carcinoma (MCC) Meeting Abstract
| Authors: | Wong, M. K. K.; Burgess, M. A.; Chandra, S.; Schadendorf, D.; Silk, A. W.; Olszanski, A. J.; Grob, J. J.; Jang, S.; Grewal, J. S.; Lewis, K. D.; Fecher, L. A.; Rabinowits, G.; Lebbe, C.; Shen, A.; Chan, T.; McGreivy, J. S.; Rothbaum, W. P.; Hanna, G. J.; Kelly, C. M. |
| Abstract Title: | Navtemadlin (KRT-232) activity after failure of anti-PD-1/L1 therapy in patients (pts) with TP53WT Merkel cell carcinoma (MCC) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680302326 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.9506 |
| Notes: | Meeting Abstract: 9506 -- Meeting also held virtually -- Source: Wos |
